Rx Price Restraint Hits McKesson; Wholesaler Sees Delay, Not Policy Change
Executive Summary
Pharmaceutical price increases remain a critical component of manufacturers' commercial strategies, McKesson CEO John Hammergren assured analysts during the Thomas Weisel Partners Healthcare Conference in Boston Sept. 9
You may also be interested in...
Pfizer Says No To “Fee-For-Service” Contracts; Cardinal, Eisai Reach Deal
Pfizer is not involved in "fee-for-service" negotiations with wholesalers, the company declared in its fourth quarter earnings release Jan. 19
Pfizer Says No To “Fee-For-Service” Contracts; Cardinal, Eisai Reach Deal
Pfizer is not involved in "fee-for-service" negotiations with wholesalers, the company declared in its fourth quarter earnings release Jan. 19
Rx Prices Will Rise 5% Prior To Start Of Medicare Drug Benefit, ABC Says
AmerisourceBergen is confident that drug prices will rise 5% ahead of the Jan. 1, 2006 start of the Medicare drug benefit, CFO Michael DiCandilo said